Showing posts with label Canada. Show all posts
Showing posts with label Canada. Show all posts

Monday, 25 April 2016

Transparent Public Pricing for Biosimilars: pCPA Releases First Principles for SEBs

Guest Blog By Arvind Mani
Director of Market Access and Policy Research
PDCI Market Access

The pan-Canadian Pharmaceutical Alliance (pCPA) recently issued a communiqué outlining their initial perspective on subsequent entry biologics (SEBs) and innovative/reference biologics as it aims to establish a SEB policy framework.

 Key Takeaways


It appears that the pCPA’s first principles for SEBs are targeted at ensuring that manufacturers of both SEB and innovative/reference products must negotiate with the pCPA – i.e. not approach individual jurisdictions to seek product listing agreements once the SEB is poised to enter the market.  Further, SEB manufacturers must be prepared for the pCPA to consider evidence beyond regulatory evaluations and health technology assessments (HTA) – perhaps this may involve reviewing international evidence.  Although this may create some uncertainty for SEB manufacturers, it appears that the pCPA balances this with a plan to ensure a competitive market – which may mean some form of preferential listing similar to what was negotiated for Inflectra. 

For manufacturers of innovative/reference biologics, these principles have clarified the pCPA’s expectations by insisting if these manufacturers put forward proposals in response to the entry of an SEB, these proposals provide national value with no incremental costs to any jurisdictions. 
Finally, the pCPA is clearly moving towards transparent prices for both SEB manufacturers and innovative/reference manufacturers who aim to renegotiate their agreements with the pCPA in anticipation of an SEB entry.  Although confidential product listing agreements are well entrenched and growing in importance for innovative products, it seems that when it comes to the SEB market, public payers are keenly focused on establishing a framework that ensures a greater level of price transparency. 

The table below summarizes pCPA’s negotiation expectations for the respective manufacturers in the SEB marketplace.

SEB Manufacturers
    Innovative/Reference Drug       Manufacturer

National Negotiation –must not approach an 
individual jurisdiction and should focus its negotiation efforts nationally with the pCPA.

National Negotiation –must not approach an individual jurisdiction and focus its negotiation nationally with the pCPA.

Broader Evidence –must be prepared for the pCPA to look at other evidence beyond the Health Canada and HTA information available.
National Value –must seek negotiations focusing on national value – i.e. no incremental costs to any individual province.

Competitive Environment –may benefit from the pCPA ensuring the creation of a competitive environment.

Transparent Price –must be prepared to not only provide a similar value to the SEB, but must include a similar or better transparent price.


Transparent Price –must provide a reduced transparent price.



pCPA First Principles for SEBs (actual communiqué)

The emergence of SEBs in the Canadian market has led the pan-Canadian Pharmaceutical Alliance (pCPA) to begin developing principles to guide more consistent negotiations for these products and related reference biologics, as the pCPA works towards establishment of a SEB policy framework.
The following first principles will guide the pCPA approach to negotiations on SEBs and reference biologics:

·         All SEB and reference biologic manufacturer proposals will only be considered through the national pCPA negotiation process rather than individual or selected jurisdictions. Determination of whether or not to proceed with negotiations with the requesting manufacturer will be made at the discretion of the pCPA.
·         Products under consideration by the pCPA will be informed by Health Canada's regulatory determinations (that the SEB products are safe and efficacious with no clinically meaningful differences with the comparator reference drugs), Health Technology Assessment recommendations, and/or other evidence or considerations as available.
·         Consistent with its mandate that includes increasing patient access to clinically and cost-effective drug treatment options, the pCPA will encourage a competitive environment that includes SEB market growth and is conducive to long-term cost reductions and sustainability for public drug plans.
·         The introduction of an SEB must provide a reduction in the drug’stransparent price to benefit all Canadians.
·         Proposals from reference biologic manufacturers will only be considered if they:
·         Provide overall national value to public drug plans and do not result inincremental costs to individual jurisdictions; and
·         Provide at least similar overall value compared to the SEB, and must include similar or better transparent price reductions if equivalent listing status is sought.
·         These first principles are a starting point and are expected to evolve through the pCPA’s engagement with stakeholders, including the pharmaceutical industry, to develop a more comprehensive SEB policy framework.



Tuesday, 9 June 2015

Ottawa Mayor Jim Watson proclaims National Cancer Survivors Day

This morning, Ottawa Mayor Jim Watson proclaimed National Cancer Survivors Day in recognition of the nearly one million cancer survivors living in Canada today. This annual celebration of life took place at City Hall in the presence of representatives of the Canadian Cancer Survivor Network and Prostate Cancer Canada Network Ottawa.
On National Cancer Survivors Day and the days following, thousands of cancer survivors and their families and supporters gather across the globe to honour cancer survivors and to show the world that life after a cancer diagnosis can be fruitful, rewarding and even inspiring. It is also a time to draw attention to the ongoing challenges of cancer survivorship in order to promote more resources, research, and survivor-friendly legislation to improve cancer survivors’ quality of life.
Mayor Watson stated that “a cancer survivor is defined as anyone living with a history of cancer – from the moment of diagnosis through the remainder of their life; there are nearly one million cancer survivors living in Canada today.”
While early diagnosis and improvements in treatment have resulted in cancer patients living longer, much remains to be done to ameliorate the physical, emotional, and financial effects of cancer on survivors as well as including cancer survivors in decision-making on issues which affect them within Canada’s cancer care and healthcare system.
The Canadian Cancer Survivor Network (CCSN) works to connect patients, survivors and other stakeholder groups with decision makers and the wider community to engage in discussion and to act on evidence-based best practices to alleviate the medical, emotional, financial and social costs of cancer and encourage research on ways to overcome barriers to optimal cancer care and follow-up for survivors in Canada.
-30-
For information or an interview please contact:
Jackie Manthorne
President & CEO
Canadian Cancer Survivor Network
613-898-1871
613-710-3636 (cell)
jmanthorne@survivornet.ca
Photos attached.
 

Tuesday, 25 November 2014

Canadian Cancer Survivor Network hosts Ontario Legislative Reception to raise awareness of metastatic prostate cancer

Ottawa, ON – November 19, 2014 – In the month of November focused on men’s health, the Canadian Cancer Survivor Network (CCSN) was pleased to host its third annual breakfast reception at the Ontario Legislature to highlight the challenges faced by metastatic prostate cancer patients and their families and the increasing number of treatment options that provide a good quality of life while living with this disease.

The reception was hosted by Ann Hoggarth, MPP for Barrie, followed by an overview of CCSN by Sapna Mahajan, CCSN Board member, who shared the personal journeys of important men in her life to illustrate why young women should be concerned about best treatment for prostate cancer.

Ann Hoggarth, MPP Barrie; Jackie Manthorne, CCSN President & CEO; Indira Naidoo-Harris, Parlimentary Assistant to the Minister of Health & Long-Term Care
Keynote speakers included Dr. Andrew Feifer, an urolic oncologist at the Trillium Health Partners’ Fidani Cancer Center at Credit Valley Hospital and Derek Lawrence, who lives with metastatic prostate cancer. Indira Naidoo-Harris, Parliamentary Assistant to Dr. Eric Hoskins, Minister of Health and Long-Term Care, Christine Elliott, Deputy Leader of the PC Party of Ontario and PC Health and Long-Term Care Critic and France Gélinas, NDP Critic, also offered remarks.

"The treatment landscape for patients with metastatic prostate cancer is changing after many years without new options. We are pleased to continue to raise awareness among Ontario MPPs of the importance of access to new treatments that can extend life that is of good quality,” said Jackie Manthorne, CCSN President and CEO. "Most awareness campaigns for prostate cancer focus on early detection and prevention and celebrate survivorship. We feel it is also important to help men living with metastatic disease to tell their stories.” 
Derek Lawrence, Jackie Manthorne, CCSN President & CEO, Dr. Andrew Feifer, Urolic Oncologist, Fidani Cancer Centre, Sapna Mahajan, CCSN Board Member

Reception sponsor MPP Ann Hoggarth shared her own cancer journey and that of other family members. MPP Indira Naidoo-Harris spoke of the government’s commitment working with patients rather than for patients while striving for world-class treatment in Ontario, and urged  MPPs to listen to patients and patient groups. Both MPP Elliott and MPP Gélinas echoed the need for access to treatment and support for caregivers; MPP Gélinas highlighted the special concerns of those from northeastern Ontario in accessing treatments where they live.  “It is wonderful to see such support and sensitivity for this issue from our members of the Ontario Legislature,” said Manthorne. 

Dr. Andrew Feifer, noted urolic oncologist at Trillium Health Partners’ Fidani Cancer Centre and the University Health Network, reminded the audience of the need for access to a variety of treatment options. He spoke about the husbands, brothers, uncles and sons that he treats, saying, “We should not – indeed cannot – fail these men in their time of need.  Our profession must deliver new therapies and treatment protocols.”

Eighty-four-year old Derek Lawrence gave a human face to the discussions that preceded his presentation. He spoke of the impact that his diagnosis has had on him and his wife Margaret. “Time is so important to those of us living with metastatic prostate cancer. I am 19 years post-diagnosis and treatments are much improved today.  As long as we can access new medicines and receive support, we can be around for a long time.”

CCSN has also recently launched A Family Affair: Prostate Cancer Family and Caregiver Portal, an online portal recognizing and addressing the experience of prostate cancer, whether in its early or more advanced stages, as a family affair. http://survivornet.ca/en/cancer_basics/prostate_cancer_family_affair_portal.

Wednesday, 8 October 2014

Participate in the consultations of the Canadian Advisory Panel on Healthcare Innovation

On June 24, 2014, Health Minister Rona Ambrose announced the creation of the Advisory Panel on Healthcare Innovation to look at creative healthcare ideas and approaches that exist in Canada and abroad, identify those that hold the greatest promise for Canada, and offer its recommendations on how the federal government can support them.

Over the next year, the Panel will seek to identify five promising areas of healthcare innovation in Canada and internationally that have the potential to reduce growth in health spending while leading to better care. The Panel will also be recommending ways in which the federal government can support those innovations.

Stakeholder consultations

As part of its work, the Panel would like to hear from stakeholders. This will be done through written submissions as well as face-to-face meetings and consultations across Canada, beginning this fall. The Panel is soliciting input on your experiences in dealing with innovation within the healthcare system and what more can be done to support it in Canada.

Stakeholder consultations are targeted at organizations and individuals involved in healthcare system innovation, such as researchers, policy makers, entrepreneurs, charities, professional associations or healthcare providers.

What is healthcare innovation?

Healthcare innovation involves a range of activities around the development, uptake and adoption of new approaches that generate value in terms of quality and safety of care, administrative efficiency, the patient experience, and patient outcomes. Innovation can occur within a single healthcare facility or department (micro-level), across a regional health system (meso-level) or at the level of a provincial, territorial or national healthcare system (macro-level).

The Panel are interested in innovation that is cost-effective (i.e. yields a meaningful improvement in health outcomes for a modest increase in expenditures), or, better yet, that is cost-neutral with improved outcomes, or results in cost savings for the health system with the same or better outcomes.
Innovation depends on the support and interaction of three critical components:

·         Practice, which encompasses people and the way they work. This is not only clinical practice, but also includes processes and interactions between clinicians and patients, clinicians and administrators, administrators and policymakers, etc.
·         Structure, which includes physical, organizational, economic, legal or other mechanisms that constrain or enable the actions of individuals in the system.
·         Culture: the shared values, perceptions and opinions of individuals, and groups of individuals, with the system.

What is the panel interested in hearing about?

Successful innovation requires partnerships that cut across multiple sectors – including governments, healthcare providers and organizations, industry and research. For success, especially at the macro-level, change is needed in practice, structure and/or culture.

The Panel would like to hear about innovation that is improving the healthcare system, and what more needs to be done. This could relate to the successful introduction of new technologies and tools, new ways of working, new ways of organizing and/or financing healthcare, new ways of capturing and using information, and much more. This is an opportunity for you to share big ideas and perspectives, which would inform The Panel’s work and ultimately the advice it provides.

The Panel is interested in receiving written briefs from stakeholders of no more than five (5) pages. To assist you in drafting your submissions, go to http://www.hc-sc.gc.ca/hcs-sss/innovation/cons/_2014/chi-cis/consult-eng.php to access a series of questions . Feel free to address some or all of these, but please ensure that your submission does not exceed five pages in length.

Submissions will be accepted by email at innovation@hc-sc.gc.ca

Public consultations

This consultation is designed to offer all Canadians a chance to provide the Panel with information about their experiences with the healthcare system.

Go to http://surveys-sondages.hc-sc.gc.ca/s/healthcare_innovation_soinsdesante/?l=en where you can provide information about having seen or experienced innovations in healthcare that you think other Canadians should know about. This could include new ways in which doctors, nurses and other healthcare workers are providing healthcare to you. It could also be about ways that you, as a patient, have taken a new role in your own healthcare. Finally, it could be about your ideas as a citizen and/or taxpayer.

This consultation began on Tuesday, September 16th, and will end on Friday, November 14th, at 11:59 p.m. EST.




Friday, 12 September 2014

New Canadian Cancer Survivor Network Chair wants patients to have more say

September 12, 2014, Ottawa, Ontario - Former breast cancer patient Elaine Dean was elected Chair of the Board of Directors of the Canadian Cancer Survivor Network (CCSN) at their recent Annual General Meeting.

Says CCSN President and CEO, Jackie Manthorne: “We are pleased to welcome Elaine as our incoming Board Chair. Her appointment will  help CCSN continue to grow as an organization to achieve our mission, which is to empower collaborative action by cancer patients, families and communities to identify and work to remove barriers to optimal patient care.”

Elaine has been a volunteer member of CCSN Board of Directors since shortly after its incorporation in November 2011. Since 1990, she has participated as a trained consumer reviewer in peer review panels here in Canada as well as in the U.S. and overseas. Elaine has also served as spokesperson on breast cancer issues for CCSN, a role she will continue as Chair.

Says Elaine: “What is unique about CCSN is its ability to represent the voice of Canadians as cancer patients and cancer survivors, with Canada’s healthcare professionals, the public and with policy makers. As an organization, we are deeply committed to sharing the latest information available to Canadians about cancer. What we would like to see, is more active engagement of patients and former patients within Canada’s healthcare community.”

More than 2 in 5 of Canadians experience a cancer diagnosis over the course of their lifetime. While improvements continue to be made in the early diagnosis and treatment of the different forms of cancer, with research ongoing to find cures, more needs to be done.

Elaine’s election by CCSN members is an indication of the growing opinion within the organization that breast cancer patient and survivor concerns need more universal understanding and attention, and a seat at the table.

Breast cancer is one of the most prevalent cancers both facing and feared by women in Canada today. Treatment is still not as effective or as coordinated as it should be, and unnecessary errors continue to be made in the diagnosis of breast cancer. Awareness continues to be a challenge, and more attention needs to be paid to the ongoing financial, emotional, family and workplace needs of Canadians and their families, who are experiencing or have experienced this disease.

To learn more about CCSN, please visit www.survivornet.ca or get engaged through social media:

Twitter: @survivornetca

Wednesday, 6 August 2014

Scientific peer review of breast cancer research applications for the department of defense

Breast cancer advocate Dianne Moore of Toronto recently participated in the evaluation of research applications submitted to the Breast Cancer Research Program (BCRP) sponsored by the US Department of Defense. Dianne was nominated for participation in the program by the Canadian Cancer Survivors Network of Ottawa. As a consumer reviewer, she was a full voting member, along with prominent scientists, at meetings to help determine how the $120 million appropriated by Congress for Fiscal Year 2014 (FY14) will be spent on future breast cancer research. 

Consumer reviewers are asked to represent the collective view of breast cancer survivors and patients, family members, and persons at risk for the disease when they prepare comments on the impact of the research on issues such as disease prevention, screening, diagnosis, treatment, and quality of life after treatment. Commenting on her role as a consumer reviewer, Dianne said that “As a breast cancer survivor and consumer reviewer, my comments were given serious consideration by the scientists and doctors and I had a vote on all the proposals that were evaluated.”

Consumer advocates and scientists have worked together in this unique partnership to evaluate the scientific merit of breast cancer research applications since 1995. To date,more than 850 consumer reviewers have served on breast cancer panels alongside scientists in the review process. Colonel Wanda L. Salzer, M.D., Director of the Congressionally Directed Medical Research Programs, expressed her appreciation for the perspectives of the consumer advocates in the scientific review sessions. "The Consumer Reviewers on each panel are instrumental in helping the scientists understand the patient's perspective and provide valuable insight into the potential impact of the proposed project. They bring with them a sense of urgency and remind all of the human element involved in medical research." 

Thousands of breast cancer research applications will be reviewed for 2014 fiscal year funds. Scientists applying propose to conduct innovative breast cancer research aimed at the elimination of breast cancer. The BCRP fills important gaps not addressed by other funding agencies by supporting groundbreaking, high-risk, high-gain research while encouraging out-of-the-box thinking. More information about the Department of Defense Breast Cancer Research Program is available at the Website: http://cdmrp.army.mil.

Friday, 20 June 2014

Canada’s federal government should be ashamed of itself!

Laurena Smith
Features Writer, Canadian Cancer Survivor Network

With the closure of the last two asbestos mines in 2011, Canada’s export industry for the toxic mineral is not expected to make a return any time soon. Even Premier Jean Charest’s promised 58 million in loans to reopen the Jeffrey Mine in aptly named Asbestos, Quebec went unfunded when the Parti Quebecois  won the 2012 provincial election by promising to keep it closed. It’s 2014, and while Liberals are back with a majority government in Quebec, but asbestos mining barely registered on the election radar [1].

Meanwhile, the Harper government is not saying whether they will be joining the over 50 countries that have banned the import and export of the known carcinogen. In fact, they are not saying much of anything at all.

Repeated questioning from the Opposition in the House of Commons has not yielded much in the way of a response.  Natural Resources Minister Greg Rickford, answering for Labour Minister Kellie Leitch after she remained silent during Question Period, stated that the government would not block the listing of chrysotile at the upcoming 2015 Rotterdam Convention [2]. The Rotterdam Convention, a United Nations treaty which includes 52 signed nations, requires the exporters of hazardous substances to disclose the risks [3].

With a dead industry and no exports, Canada has little reason to block the list of the mineral. 
Harper’s Quebec lieutenant, Christian Paradis explained that because the previous Parti Québécois government refused to revive the bankrupt Quebec asbestos industry, causing its shutdown, there was no point in Canada blocking the listing of chrysotile asbestos. As economic interest waned, the government had no issues with changing their stance, never mind the very real health threat the mineral poses to Canadians.

Ottawa’s position maintains that chrysotile, the ‘less deadly’ version of other asbestiform minerals, when handled safely and responsibly poses only a minimal health risk. Health Canada states, ‘it is generally accepted that chrysotile asbestos is less potent and does less damage to the lungs’ [4]; yet chrysotile represented 95 per cent of all asbestos used over the past century [5]. It also remains the top killer in Canadian workplaces and is responsible for a reported 2,268 on-the-job deaths from 2007-2012 [6]. This does not account for deaths which occurred outside the workplace.

Exposure to asbestos remains a major issue: older schools, hospitals, homes and building materials can contain the substance, leaving many Canadians to become exposed without their knowledge [7]. Furthermore, neglect of safety procedure when removing asbestos from properties can endanger not only workers but people in nearby vicinities, their families, friends and other bystanders [8]. Exposure to these fibres can cause painful lung-related diseases, including two deadly forms of cancer: mesothelioma and lung cancer [9].

As more asbestos is uncovered, demolished, and removed; rates of mesothelioma, a cancer caused almost exclusively by exposure to asbestos, are expected to rise dramatically. Once diagnosed with mesothelioma, individuals are expected to only live between six months and a year [10]. The Canadian government has a responsibility to protect not only those individuals affected by mesothelioma, but to ban and remove asbestos completely from the Canadian market and ensure the standards for the safe removal of asbestos are met.

References

[1]"Asbestos Mine Was Not An Issue in 2014 Quebec Election." Asbestos Facts Canada. Asbestos Facts Canada, 11 May 2011. Web. 18 June 2014. <http://asbestosfacts.ca/information/asbestos-issue-2014-quebec-election/>.
[2] Galloway, Gloria. "Government Silent as Questions Mount about Asbestos Danger." The Globe and Mail. The Globe and Mail, 17 June 2014. Web. accessed 18 June 2014. <http://www.theglobeandmail.com/news/politics/federal-opposition-raises-asbestos-policy-issue/article19214039/>.
[3] "No Safe Use: The Canadian Asbestos Epidemic That Ottawa Is Ignoring." The Globe and Mail. The Globe and Mail, 14 June 2014. Web. accessed 18 June 2014. <http://www.theglobeandmail.com/report-on-business/no-safe-use-as-the-top-workplace-killer-asbestos-leaves-a-deadly-legacy/article19151351/>.
[4] "Health Risks of Asbestos." Health Canada. Government of Canada, 14 Oct. 2012. Web.  accessed 18 June 2014. <http://healthycanadians.gc.ca/environment-environnement/outdoor-air-exterieur/asbestos-amiante-eng.php>.
[6] "No Safe Use: The Canadian Asbestos Epidemic That Ottawa Is Ignoring." The Globe and Mail. The Globe and Mail, 14 June 2014. Web. accessed 18 June 2014. <http://www.theglobeandmail.com/report-on-business/no-safe-use-as-the-top-workplace-killer-asbestos-leaves-a-deadly-legacy/article19151351/>.
[7] ibid.
[8] ibid.
[9] "What Are Asbestos-Related Lung Diseases?" NIH. National Heart, Lung and Blood Institute, 1 May 2011. Web. accessed 18 June 2014. <http://www.nhlbi.nih.gov/health/health-topics/topics/asb/>.
[10] "No Safe Use: The Canadian Asbestos Epidemic That Ottawa Is Ignoring." The Globe and Mail. The Globe and Mail, 14 June 2014. Web. accessed 18 June 2014. <http://www.theglobeandmail.com/report-on-business/no-safe-use-as-the-top-workplace-killer-asbestos-leaves-a-deadly-legacy/article19151351/>.

Friday, 25 April 2014

What do cancer patients want?
By Jackie Manthorne
Presented at the Economic Club of Canada
April 14, 2014

Thank you very much for your kind introduction. And I would also like to thank all of you for attending today! I was hoping that Toronto wouldn’t be having a blizzard and that we all wouldn’t be sporting boots, parkas and tuques! Last week I was in Gatineau, where there was sleet, Vancouver and Victoria, where it was warm and the cherry blossoms were blooming and the trees were green, on to Edmonton, where it was warm but damp, and finally to Calgary, where the wet snow was temporary, so my sense is that right across the country, spring is finally emerging from our long, cold winter!

What do cancer patients want? Those of us working and volunteering at the Canadian Cancer Survivor Network strongly believe in the mantra “Nothing about us without us;” after all, patients, survivors and caregivers are the experts: they are living the cancer journey. So the first step in finding out what patients want is to ask them and then listen closely to their responses so we can work with them to find solutions to issues they identify as important to them. More often than not, these issues pinpoint gaps in our healthcare and cancer care systems.

Last year the Canadian Cancer Survivor Network conducted a members’ survey in which we asked what patients want, and much of what I am going to talk about today is what they responded and the conclusions we can draw from these responses.

Overall, patients told us that they were concerned about:

·         The physical side effects of treatment and surgery and psychosocial or mental health issues.
·         Changing family dynamics.
·         Financial issues and difficulties transitioning back to work.
·         Fear of cancer spreading or coming back.

The physical and mental side effects of treatment are wide-ranging and are the primary concern of cancer patients and survivors.  Survey respondents reported many physical side effects from their treatment and surgery.  These include lymphedema, facial and intestinal reconstruction, neuropathy, and other debilitating physical issues. Pain resulting from nerve damage, scar tissue, and surgery is a continuing issue for many patients and survivors.

Patients told us:

·         “I had a significant defect on my face from reconstruction, so dealing with seeing it every day was tough.” 
·         “Chemobrain. I mean, memory issues, difficulty sequencing. Not being able to keep up with others.”
·         “Fatigue.”
·         “Impotence and incontinence after prostate cancer treatment.”
·         “Radiation caused rib pain for two years.”
·          “I developed neuropathy which I would like to go away.”
·         “I had bladder cancer, and incontinence is an issue I have had to face; although I understood that this can happen after treatment and surgery, it is hard to face day after day.”

Mental or psychological side effects patients told us about include:

·         “I struggle with body image issues after my mastectomy.”
·         “Fear of dying before my children grow up.”
·         “It is generally thought that once you have completed treatment and a certain time has passed, you are now ‘cured.’ There is little understanding of the fear and anxiety that every survivor feels that it could return.”
·         “Fear, stress and isolation.”
·         “I became the problem; I am no longer seen as a problem solver by my children.”
·         “It's a strange world when you're 30 and anyone else you've known that's had cancer is dead.”

Some patients reported seeking help, but many reported working through these and other psychological issues on their own, with family and friends, or in cancer support groups.

Lymphedema, or swelling in the arms or legs, is a serious and frequent concern among cancer patients and survivors. It can occur right away, or years after treatment ends.  Aside from the physical problems it creates, it is also a barrier to returning to work and the cause of additional costs, since government coverage of sleeves is uneven across the country, and patients without a health care plan must pay for physiotherapy, and those with plans often max them out before year end.

One patient who responded to our survey said, “The health care system should be paying for my lymphatic drainage massage. It is very costly, approximately $90 an hour, and now I'm on CPP disability and simply can't afford it. Yet, I need it! There is no financial support for treatment of lymphedema and this is so unacceptable.”

An Ottawa friend who subsequently died from metastatic breast cancer had such severe lymphedema in her left arm that it would pull her off a chair if she casually bent to pick up something on the floor without thinking about it and planning her movements first. Another patient in Montreal suffering from cancer of unknown primary developed lymphedema in both legs and was no longer able to go to her office to work; luckily, she was able to work from home, although she was in constant pain, and her income was reduced.

How can we help patients deal with the physical side effects of treatment and surgery and psychosocial or mental health issues?

CCSN has been speaking to politicians and other decision-makers about establishing rehabilitation services for all cancer patients and survivors suffering from lymphedema and other ongoing side effects, no matter when they occur in each patient or survivor’s cancer journey. Heart attack and stroke patients and those receiving joint replacements receive rehabilitation to help them recover, get back to work, and go on with their lives. While some patients in our survey reported receiving some rehabilitation services post-treatment, most did not. Without similar services for cancer patients, ongoing side effects from surgery and treatment may continue to impede total recovery.
Most patients reported a sense of abandonment once their cancer treatment ended:

·         “I am having to deal with the loss of the people and trust that was there while everything was being done from the very beginning and to the last day of radiation.”
·         “The 'safety net' was gone once I stopped all the visits to the specialists.”
·         “Once treatment was finished, I was on my own, working with my family doctor. If I had any issues regarding the cancer or problems from treatment, I would always ask myself, how much does a family physician know about cancer? I was always thinking that hopefully, he knows what he is talking about!”

This strong feeling of abandonment among cancer patients is so widespread that the Canadian Cancer Survivor Network has been discussing the feasibility of continuing cancer patient navigation post-treatment with provincial politicians and other decisions makers. This would enable patients, survivors and caregivers to access information, services and help from cancer experts whenever they need it.  Ongoing cancer navigation should also help prevent the late diagnosis of recurrences and metastasises and result in a better quality of life for survivors who still suffer from treatment side effects.

Another important issue that patients have identified is changes in family dynamics.

Our survey is not the first to bring to light the physical ramifications of cancer treatment on sexual function and intimacy, which may cause additional mental health issues.  Body image issues are cited, as are emotional distance and in some cases separation from spouses or partners. Respondents cited loss of intimacy and the ability to fulfill a partner’s needs as a frequent side effect of treatment:

·         “I have trouble feeling close to my spouse at times, and I feel no sexual desire.”
·         “My husband became physically distant. He was very helpful and always supportive but we never made love after the chemo. Now, nine years later, it is okay.”
Several patients reported that their relationships ended as a result of their cancer.  Partners were reportedly unable to deal with the challenges and left because of the loss of intimacy, or cheated on the cancer patient or survivor. These occurrences were linked to a sense of isolation and depression. Relationships with children, parents and other family members sometimes changed as well.

·         “One child wanted to help me, but he was physically affected by stomach pain and worried a lot. The other child could not cope to see me so ill and went to live with his father for a while. My partner seemed supportive; however, he went off to have an affair with someone who was very well endowed. We are no longer together.”
·         “I was a single mom wishing to spend more time with my adult child. She was afraid she may contract cancer and shunned me. She had difficulty being around me and seeing me vulnerable.”
·         “Three days after diagnosis, my boyfriend left as he ‘couldn't handle it.’ I found people didn't know what to say to you or they expected you to be back to 'normal' when you are feeling anything but normal.  And when I was concerned about a recurrence, my mother unintentionally said some damaging words that put a strain on our relationship for a while.  She just didn't know what to say, and told me ‘well, at least you've lived a good life.’ I was 36!”
However, the effects of cancer on patients’ relationships with the partner and family can also bring people closer together. Many patients also reported that their relationships had improved post-diagnosis, with families being drawn closer together and priorities made clear. Some patients who had suffered a broken relationship reported that their new relationships were stronger than their previous, broken relationships.

·         “I think my family is valuing me more.”
·         “My husband and I have always been close, but we are even closer now, realizing that life is short.  Little things no longer bother us.”
·         “We are more open and honest about everything:  health, emotions, love and well-being. It has created a close bond between me and my entire family.”
·         “Got divorced. But got a new partner. Life improved greatly.”
·         “We are a lot closer and tell each other "I love you" on a daily basis.”

Again, access to continuing cancer patient navigation services would enable patients, survivors, caregivers and family members to deal with not only the ongoing physical side effects of cancer surgery and treatment, but also the psychological issues and adjustment to changed family dynamics and the “new normal” patients and their families experience.

An additional concern expressed in our survey of members relates to financial issues and difficulties transitioning back to work.
The Canadian Cancer Society, Manitoba Division and the Canadian Cancer Action Network’s study entitled Five-Year Action Plan to Address the Financial Hardship of Cancer in Canada: A Call for Action was the most recent of several studies of financial issues experienced by cancer patients.[i]

Study findings included the following:

“Nine out of ten Canadian families touched by cancer reported some form of financial challenge as incomes declined and household costs rose. For some, a cancer diagnosis started a financial tailspin that pushed ordinary people over the edge, resulting in debt, distress, bankruptcy and even a lifetime on social assistance.

“What emerged in this study was a consistent picture of financial hardship caused not by a single challenge but rather a combination of factors that created a perfect storm as sick leave and vacation time was used up and costs increased because of day-to-day living costs and unforeseen expenses from drugs and medical equipment to child care and travel increased. Surprisingly, parking costs at treatment facilities were more than a minor irritant, they were a major expense.

The report went on to say that, “These issues are compounded by a third factor:  A lack of awareness and a false sense of security have left Canadians unprepared to deal with these challenges, both as individuals and as a society. Most Canadians do not know that a cancer diagnosis has caused some people to declare bankruptcy, lose their homes, lose all of their savings, make less than optimal treatment decisions or become dependent on taxpayer-funded programs for the rest of their lives. Until cancer comes into their own lives, they believe the myth that all health care is free. Most never imagined that they could face such difficult challenges at such a vulnerable time of their lives. The reality comes as a shock to many.”  
This shock and frustration was voiced by many patients who responded to our survey:

·         “I had complications and multiple surgeries, which had me off work for three years. I was single, self-employed and had previous employment doing physical work as a home support worker. I had no money coming in and had to spend my savings to live for three years.”
·         “I received a very small amount of medical financial assistance from the government.  I needed to have it supplemented by asking friends and family for assistance, as what the government paid wouldn't even pay my rent.  The government then said I could not receive 'any' funds if I was receiving assistance privately.”
·         “Even when you have a job and benefits, you still take a big hit financially, especially if you are the only wage earner. A lot of us have difficulties making ends meet while working, and when your salary is cut even further, it’s a major juggling act.  Also, after cancer the cost of medications are very expensive. If there are changes made in your life that affects your medical plan, you are basically screwed and have to pay for your medications. Again, another juggling act. Do I take the medication and let other things slide, or take the chance that I will get cancer again if I don't take the medication? In the end you still end up with financial difficulties.”

A recent Léger survey fielded by the Canadian Cancer Survivor Network also shed new light on the striking financial, decision-making and emotional burden the disease puts on cancer patients and their caregivers. 301 cancer patients and 201 caregivers participated in this survey, making it one of the largest caregiver surveys that we are aware of and providing new and important information on the role of caregivers in their loved ones’ cancer journeys. In fact, caregivers reported more difficulties in accessing treatment and necessary medications, difficulty finding flexible work options and loss of salaries than patients, which clearly points to caregivers’ role as cancer care navigators and managers. While one in five patients experienced difficulty in finding flexible work options while battling cancer, nearly one half of caregivers struggled to integrate care for loved ones into their work schedules, making the management of the disease and their income very challenging.

As such, the Canadian Cancer Survivor Network strongly recommends that caregivers, who reported receiving no significant outside help other than from friends and families, should not be left to fend for themselves. Caregivers should join patients in the centre of the circle as we move toward defining and implementing patient-centered care.

And to add insult to injury, Employment Insurance Sickness Benefits last only 15 weeks, certainly not long enough for someone going through cancer treatment, and Canadian Pension Plan Disability Benefits are extremely difficult to access. CCSN will continue to raise awareness among decision makers of this gap in our social support system and to push for change so that cancer patients are not cut off EI Sickness Benefits in the middle of treatment, and often forced to return to work before they are ready.

Return to work was often a struggle:

·         “I made the transition back to work, but it was an effort. My employer tried to reduce my hours from a full-time to part-time job.”
·         “I had a very slow recovery due to high doses of chemo. I was let go from my job as I could not return to work full time in six weeks.”
·         “The resulting lymphedema in my left leg due to tumour removal has limited the time I can spend standing. I can now work as a teacher only part-time instead of full- time.”
·         “When I went back to work, my manager promoted a junior above me in case I got sick again. I left that place of employment but never found another place I enjoyed as much.”

Financial issues identified by patients also include lack of timely access to drugs and medications as well as the cost of drugs already alluded to above.

When you are diagnosed with cancer, you want timely access to the best medicines to stop your cancer in its tracks, to prevent it from recurring, and to stop it from spreading.  If it has spread, you want immediate access to the best medicines to stop it from progressing and to maintain pain-free quality of life.

But depending on where you live in this country, you may not have timely access to the best medicines, and even if you do, you may not be able to afford them!

The Léger survey revealed worrisome gaps in access to drugs: one in six patients and nearly one-third of caregivers reported difficulty in accessing current or effective treatment options and reimbursement of drug costs. And over one in 20 patients and one in five caregivers experienced difficulty in accessing medicine, When you translate this into the number of Canadians who are likely to develop cancer in their lifetime – two in five, according to the Canadian Cancer Society, we are talking about thousands of people who have difficulty accessing cancer meds every year.

One patient who responded to our survey of members said this: “Make all cancer drugs available. Some are not available even though they have been shown to be beneficial. Also new drugs are often not funded and are slow to enter the system. These drugs are too expensive for most people to afford. The alternative is to die. Think of that if you can.”

Why is this so?

One reason is the long and winding road of drug approval in Canada, starting with Health Canada and proceeding through either the pan-Canadian Oncology Drug Review or the Common Drug Review and continuing through each province and territory, with the addition of the Council of the Federation’s Pan-Canadian Pricing Alliance.  Creating solutions to the long delays in drug approval is beyond the scope of this talk, but there is certainly an unacceptable delay in accessing new medicines, often years. It is unclear what consequences these long wait times for access to new drugs have on patients. Are some patients not receiving the gold standard of treatment compared to patients in other countries? Certainly there are no safe wait times for patients living with metastatic cancer.

A second reason for access difficulties experienced by patients is the fact that healthcare is a provincial/territorial responsibility, and public coverage of any given cancer drug (or any prescription drug, for that matter), varies from province to province – a postal code lottery of drug access. What is available in one province may not be in another, despite the fact that the drug in question has been approved for use in Canada. Or, it may be available under the formulary in one province but not in another.

Making cancer medications available and affordable to all Canadians is not only fair, it also makes economic sense.  I might add that we are working on this issue in coalition with our over 40 partner groups as well as stakeholders in other chronic disease organizations.

Overall, survivors face difficulty with the loss of healthcare interactions, returning to work, and affording treatment costs.
·         Regardless of their experience with treatment, the sentiment of abandonment by the healthcare system or lack of post-treatment care was widespread.  The most common example given was lack of access to healthcare professionals post-treatment.
·         Many patients, survivors and caregivers expressed a desire for additional support in paying for drugs and other treatment-related items (i.e. lymphatic drainage massage, PSA testing, needles).  There was a sense of annoyance at the lack of or insufficient funding for survivors.
·         Barriers to returning to work were primarily physical – fatigue, lymphedema, or other side effects of surgery or treatment.  Some survivors also said that they were forced to leave their jobs due to cancer-related fatigue or complications.
·         Depression, anxiety, isolation and other mental issues were also identified as barriers to maintaining to a normal life, work, and functional relationships and family life.
·         Some patients had positive experiences returning to work or working through their treatment, but companies were identified as making efforts to ensure that the survivor was able to come back to work.

I have made suggestions about how some of these issues can be better dealt with by our healthcare and cancer care system, including making ongoing, lifelong cancer navigation available post-treatment to patients, caregivers and families and re-visioning recovery from cancer and the side effects of surgery and treatment as a rehabilitative issue.

The Canadian Cancer Survivor Network works to connect patients, survivors and other stakeholder groups with decision makers and the wider community to engage in discussion and to act on evidence-based best practices to alleviate the medical, emotional, financial and social costs of cancer and encourage research on ways to overcome barriers to optimal cancer care and follow-up for survivors in Canada.

We invite you to join us in this work.
Thank you.




[i] http://www.cancer.ca/en/get-involved/take-action/what-we-are-doing/financial-hardship-of-cancer-in-canada-mb/?region=mb